Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 365

1.

Distribution of Molecular Subtypes in Muscle-invasive Bladder Cancer Is Driven by Sex-specific Differences.

de Jong JJ, Boormans JL, van Rhijn BWG, Seiler R, Boorjian SA, Konety B, Bivalacqua TJ, Wheeler T, Svatek RS, Douglas J, Wright J, Dall'Era M, Crabb SJ, Efstathiou JA, van der Heijden MS, Mouw KW, Miyamoto DT, Lotan Y, Black PC, Gibb EA, Porten SP.

Eur Urol Oncol. 2020 Mar 20. pii: S2588-9311(20)30035-3. doi: 10.1016/j.euo.2020.02.010. [Epub ahead of print]

PMID:
32205136
2.

Comparing Provider-Led Sexual Health Counseling of Male and Female Patients Undergoing Radical Cystectomy.

Gupta N, Kucirka LM, Semerjian A, Wainger J, Pierorazio PM, Herati AS, Bivalacqua TJ.

J Sex Med. 2020 Mar 11. pii: S1743-6095(20)30062-X. doi: 10.1016/j.jsxm.2020.01.025. [Epub ahead of print]

PMID:
32171630
3.

A Genomic Classifier for Predicting Clinically Aggressive Luminal Bladder Tumors with Higher Rates of Pathological Upstaging.

de Jong JJ, Liu Y, Boorjian SA, Bivalacqua TJ, Porten SP, Wheeler T, Davicioni E, Svatek RS, Boormans JL, Black PC, Lotan Y, Gibb EA.

J Urol. 2020 Feb 14:101097JU0000000000000798. doi: 10.1097/JU.0000000000000798. [Epub ahead of print]

PMID:
32074006
4.

Impact of sex on response to neoadjuvant chemotherapy in patients with bladder cancer.

D'Andrea D, Black PC, Zargar H, Zargar-Shoshtari K, Zehetmayer S, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, Sridhar SS, McGrath JS, Aning J, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Daneshmand S, Spiess PE, Shariat SF.

Urol Oncol. 2020 Feb 11. pii: S1078-1439(20)30011-9. doi: 10.1016/j.urolonc.2020.01.010. [Epub ahead of print]

PMID:
32057595
5.

Reducing preoperative blood orders and costs for radical prostatectomy.

Gupta N, Visagie M, Kajstura TJ, Han M, Trock B, Gehrie EA, Frank SM, Bivalacqua TJ.

J Comp Eff Res. 2020 Feb;9(3):219-226. doi: 10.2217/cer-2019-0126. Epub 2020 Feb 11.

PMID:
32043362
6.

Multi-Institution Evaluation of Sequential Gemcitabine and Docetaxel as Rescue Therapy for Nonmuscle Invasive Bladder Cancer.

Steinberg RL, Thomas LJ, Brooks N, Mott SL, Vitale A, Crump T, Rao MA, Daniels MJ, Wang J, Nagaraju S, DeWolf WC, Lamm DL, Kates M, Hyndman ME, Kamat AM, Bivalacqua TJ, Nepple KG, O'Donnell MA.

J Urol. 2019 Dec 10:101097JU0000000000000688. doi: 10.1097/JU.0000000000000688. [Epub ahead of print]

PMID:
31821066
7.

Reply by Authors.

Chappidi MR, Stimson CJ, Kates M, Odisho AY, Bivalacqua TJ.

J Urol. 2020 Mar;203(3):552-553. doi: 10.1097/JU.0000000000000522.03. Epub 2019 Nov 26. No abstract available.

PMID:
31769720
8.

Identification of Candidates for Salvage Therapy: The Past, Present, and Future of Defining Bacillus Calmette-Guérin Failure.

Becker REN, Kates MR, Bivalacqua TJ.

Urol Clin North Am. 2020 Feb;47(1):15-21. doi: 10.1016/j.ucl.2019.09.004. Review.

PMID:
31757296
9.

Adaptive Immune Resistance to Intravesical BCG in Non-Muscle Invasive Bladder Cancer: Implications for Prospective BCG-Unresponsive Trials.

Kates M, Matoso A, Choi W, Baras AS, Daniels MJ, Lombardo K, Brant A, Mikkilineni N, McConkey DJ, Kamat AM, Svatek RS, Porten SP, Meeks JJ, Lerner SP, Dinney CP, Black PC, McKiernan JM, Anderson C, Drake CG, Bivalacqua TJ.

Clin Cancer Res. 2020 Feb 15;26(4):882-891. doi: 10.1158/1078-0432.CCR-19-1920. Epub 2019 Nov 11.

PMID:
31712383
10.

Evaluation of Incisional Negative Pressure Wound Therapy in the Prevention of Surgical Site Occurrences After Radical Cystectomy: A New Addition to Enhanced Recovery After Surgery Protocol.

Joice GA, Tema G, Semerjian A, Gupta M, Bell M, Walker J, Kates M, Bivalacqua TJ.

Eur Urol Focus. 2019 Nov 5. pii: S2405-4569(19)30292-5. doi: 10.1016/j.euf.2019.09.016. [Epub ahead of print]

PMID:
31704281
11.

Total Penis, Scrotum, and Lower Abdominal Wall Transplantation.

Redett RJ 3rd, Etra JW, Brandacher G, Burnett AL, Tuffaha SH, Sacks JM, Shores JT, Bivalacqua TJ, Bonawitz S, Cooney CM, Coon D, Pustavoitau A, Rizkalla NA, Jackson AM, Javia V, Fidder SAJ, Davis-Sproul J, Brennan DC, Sander IB, Shoham S, Sopko NA, Lee WPA, Cooney DS.

N Engl J Med. 2019 Nov 7;381(19):1876-1878. doi: 10.1056/NEJMc1907956. No abstract available.

PMID:
31693813
12.

The prognostic value of the neutrophil-to-lymphocyte ratio in patients with muscle-invasive bladder cancer treated with neoadjuvant chemotherapy and radical cystectomy.

Black AJ, Zargar H, Zargar-Shoshtari K, Fairey AS, Mertens LS, Dinney CP, Mir MC, Krabbe LM, Cookson MS, Jacobsen NE, Griffin J, Montgomery JS, Vasdev N, Yu EY, Xylinas E, Campain NJ, Kassouf W, Dall'Era MA, Seah JA, Ercole CE, Horenblas S, McGrath JS, Aning J, Shariat SF, Wright JL, Thorpe AC, Morgan TM, Holzbeierlein JM, Bivalacqua TJ, North S, Barocas DA, Lotan Y, Grivas P, Stephenson AJ, Shah JB, van Rhijn BW, Spiess PE, Daneshmand S, Sridhar SS, Black PC.

Urol Oncol. 2020 Jan;38(1):3.e17-3.e27. doi: 10.1016/j.urolonc.2019.09.023. Epub 2019 Oct 31.

PMID:
31676278
13.

Impact of spheroid culture on molecular and functional characteristics of bladder cancer cell lines.

Yoshida T, Sopko NA, Kates M, Liu X, Joice G, Mcconkey DJ, Bivalacqua TJ.

Oncol Lett. 2019 Nov;18(5):4923-4929. doi: 10.3892/ol.2019.10786. Epub 2019 Aug 29.

14.

Circulating Tumor Cell and Circulating Tumor DNA Assays Reveal Complementary Information for Patients with Metastatic Urothelial Cancer.

Chalfin HJ, Glavaris SA, Gorin MA, Kates MR, Fong MH, Dong L, Matoso A, Bivalacqua TJ, Johnson MH, Pienta KJ, Hahn NM, McConkey DJ.

Eur Urol Oncol. 2019 Sep 25. pii: S2588-9311(19)30130-0. doi: 10.1016/j.euo.2019.08.004. [Epub ahead of print]

PMID:
31563523
15.

A Nationally Representative Study of Nonindex Hospital Readmissions following Radical Prostatectomy: Implications for Bundled Payment Models.

Chappidi MR, Stimson CJ, Kates M, Odisho AY, Bivalacqua TJ.

J Urol. 2020 Mar;203(3):546-553. doi: 10.1097/JU.0000000000000522. Epub 2019 Sep 3.

PMID:
31479405
16.

An evaluation of monthly maintenance therapy among patients receiving intravesical combination gemcitabine/docetaxel for nonmuscle-invasive bladder cancer.

Daniels MJ, Barry E, Milbar N, Schoenberg M, Bivalacqua TJ, Sankin A, Kates M.

Urol Oncol. 2020 Feb;38(2):40.e17-40.e24. doi: 10.1016/j.urolonc.2019.07.022. Epub 2019 Aug 28.

PMID:
31473090
17.

Penile Allotransplantation: Pushing the Limits.

Hawksworth DJ, Cooney DS, Burnett AL, Bivalacqua TJ, Redett RJ.

Eur Urol Focus. 2019 Jul;5(4):533-535. doi: 10.1016/j.euf.2019.08.004. Epub 2019 Aug 23.

PMID:
31447389
18.

Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer.

Joice GA, Bivalacqua TJ, Kates M.

Nat Rev Urol. 2019 Oct;16(10):599-612. doi: 10.1038/s41585-019-0220-4. Epub 2019 Aug 21. Review.

PMID:
31434998
19.

Combined Next-generation Sequencing and Flow Cytometry Analysis for an Anti-PD-L1 Partial Responder over Time: An Exploration of Mechanisms of PD-L1 Activity and Resistance in Bladder Cancer.

Kates M, Nirschl TR, Baras AS, Sopko NA, Hahn NM, Su X, Zhang J, Kochel CM, Choi W, McConkey DJ, Drake CG, Bivalacqua TJ.

Eur Urol Oncol. 2019 Feb 26. pii: S2588-9311(19)30025-2. doi: 10.1016/j.euo.2019.01.017. [Epub ahead of print]

PMID:
31411999
20.

Spotlight on Sexual Medicine: Advances and Issues of Debate.

Bivalacqua TJ.

Eur Urol Focus. 2019 Jul;5(4):525. doi: 10.1016/j.euf.2019.07.006. Epub 2019 Aug 9. No abstract available.

PMID:
31405620
21.

Predictive biomarkers for drug response in bladder cancer.

Yoshida T, Kates M, Fujita K, Bivalacqua TJ, McConkey DJ.

Int J Urol. 2019 Nov;26(11):1044-1053. doi: 10.1111/iju.14082. Epub 2019 Aug 1. Review.

PMID:
31370109
22.

Contemporary oncologic outcomes of second induction course BCG in patients with nonmuscle invasive bladder cancer.

Daniels MJ, Barry E, Schoenberg M, Lamm DL, Bivalacqua TJ, Sankin A, Kates M.

Urol Oncol. 2020 Jan;38(1):5.e9-5.e16. doi: 10.1016/j.urolonc.2019.05.018. Epub 2019 Jun 27.

PMID:
31255541
23.

Regenerative and engineered options for urethroplasty.

Pederzoli F, Joice G, Salonia A, Bivalacqua TJ, Sopko NA.

Nat Rev Urol. 2019 Aug;16(8):453-464. doi: 10.1038/s41585-019-0198-y. Epub 2019 Jun 6. Review.

PMID:
31171866
24.

Molecular Subtyping of Clinically Localized Urothelial Carcinoma Reveals Lower Rates of Pathological Upstaging at Radical Cystectomy Among Luminal Tumors.

Lotan Y, Boorjian SA, Zhang J, Bivalacqua TJ, Porten SP, Wheeler T, Lerner SP, Hutchinson R, Francis F, Davicioni E, Svatek RS, Chen CL, Black PC, Gibb EA.

Eur Urol. 2019 Aug;76(2):200-206. doi: 10.1016/j.eururo.2019.04.036. Epub 2019 May 12.

PMID:
31092337
25.

Diagnosis of urothelial carcinoma in situ using blue light cystoscopy and the utility of immunohistochemistry in blue light-positive lesions diagnosed as atypical.

Pederzoli F, Murati Amador B, Samarska I, Lombardo KA, Kates M, Bivalacqua TJ, Matoso A.

Hum Pathol. 2019 Aug;90:1-7. doi: 10.1016/j.humpath.2019.04.018. Epub 2019 May 6.

PMID:
31071342
26.

Clinical significance of urothelial carcinoma ambiguous for muscularis propria invasion on initial transurethral resection of bladder tumor.

Hassan O, Murati Amador B, Lombardo KA, Salles D, Cuello F, Marwaha AS, Daniels MJ, Kates M, Bivalacqua TJ, Matoso A.

World J Urol. 2020 Feb;38(2):389-395. doi: 10.1007/s00345-019-02782-y. Epub 2019 Apr 27.

PMID:
31030230
27.

Incidence and distribution of UroSEEK gene panel in a multi-institutional cohort of bladder urothelial carcinoma.

Eich ML, Rodriguez Pena MDC, Springer SU, Taheri D, Tregnago AC, Salles DC, Bezerra SM, Cunha IW, Fujita K, Ertoy D, Bivalacqua TJ, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Netto GJ.

Mod Pathol. 2019 Oct;32(10):1544-1550. doi: 10.1038/s41379-019-0276-y. Epub 2019 Apr 25.

28.

Tumor immune microenvironment in non-muscle-invasive urothelial carcinoma of the bladder.

Eich ML, Chaux A, Guner G, Taheri D, Mendoza Rodriguez MA, Rodriguez Peña MDC, Baras AS, Hahn NM, Drake C, Sharma R, Bivalacqua TJ, Rezaei K, Netto GJ.

Hum Pathol. 2019 Jul;89:24-32. doi: 10.1016/j.humpath.2019.04.003. Epub 2019 Apr 24.

PMID:
31026471
29.

Blue light flexible cystoscopy with hexaminolevulinate in non-muscle-invasive bladder cancer: review of the clinical evidence and consensus statement on optimal use in the USA - update 2018.

Lotan Y, Bivalacqua TJ, Downs T, Huang W, Jones J, Kamat AM, Konety B, Malmström PU, McKiernan J, O'Donnell M, Patel S, Pohar K, Resnick M, Sankin A, Smith A, Steinberg G, Trabulsi E, Woods M, Daneshmand S.

Nat Rev Urol. 2019 Jun;16(6):377-386. doi: 10.1038/s41585-019-0184-4. Review.

PMID:
31019310
30.

Intratunical injection of autologous adipose stromal vascular fraction reduces collagen III expression in a rat model of chronic penile fibrosis.

Hakim L, Fiorenzo S, Hedlund P, Montorsi F, Bivalacqua TJ, De Ridder D, Weyne E, Ralph D, Garaffa G, Muneer A, Joniau S, Albersen M, Castiglione F; Trauma and Reconstructive Urology Working Party of the European Association of Urology (EAU) Young Academic Urologists (YAU).

Int J Impot Res. 2019 Apr 15. doi: 10.1038/s41443-019-0136-9. [Epub ahead of print]

PMID:
30988428
31.

Molecular Characterization of Neuroendocrine-like Bladder Cancer.

Batista da Costa J, Gibb EA, Bivalacqua TJ, Liu Y, Oo HZ, Miyamoto DT, Alshalalfa M, Davicioni E, Wright J, Dall'Era MA, Douglas J, Boormans JL, Van der Heijden MS, Wu CL, van Rhijn BWG, Gupta S, Grivas P, Mouw KW, Murugan P, Fazli L, Ra S, Konety BR, Seiler R, Daneshmand S, Mian OY, Efstathiou JA, Lotan Y, Black PC.

Clin Cancer Res. 2019 Jul 1;25(13):3908-3920. doi: 10.1158/1078-0432.CCR-18-3558. Epub 2019 Apr 5.

PMID:
30952638
32.

In Reply.

Brennen WN, Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Denmeade SR.

Stem Cells Transl Med. 2019 Jul;8(7):739-740. doi: 10.1002/sctm.19-0068. Epub 2019 Mar 29. No abstract available.

33.

A Systematic Review on Ischemic Priapism and Immediate Implantation: Do We Need More Data?

Capece M, La Rocca R, Mirone V, Bivalacqua TJ, Castiglione F, Albersen M, Ralph DJ, Muneer A, Garaffa G.

Sex Med Rev. 2019 Jul;7(3):530-534. doi: 10.1016/j.sxmr.2018.10.007. Epub 2019 Mar 19. Review.

PMID:
30898595
34.

Immunotherapy in nonmuscle invasive bladder cancer: current and emerging treatments.

Gupta M, Kates M, Bivalacqua TJ.

Curr Opin Oncol. 2019 May;31(3):183-187. doi: 10.1097/CCO.0000000000000533. Review.

PMID:
30893148
35.

Prognostic implications of prostatic urethral involvement in non-muscle-invasive bladder cancer.

Brant A, Daniels M, Chappidi MR, Joice GA, Sopko NA, Matoso A, Bivalacqua TJ, Kates M.

World J Urol. 2019 Dec;37(12):2683-2689. doi: 10.1007/s00345-019-02673-2. Epub 2019 Mar 8.

PMID:
30850856
36.

The Urogenital Epithelium and Corporal Tissues Are the Primary Targets of Rejection in Penile Vascularized Composite Allotransplantation: A New Real-Time Tissue-Based Monitoring System.

Lough DM, Sopko NA, Matsui H, Miller D, Swanson EW, Bluebond-Langner R, Brandacher G, Burnett AL, Bivalacqua TJ, Redett RJ.

Plast Reconstr Surg. 2019 Mar;143(3):534e-544e. doi: 10.1097/PRS.0000000000005377.

PMID:
30817651
37.

A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer.

Schweizer MT, Wang H, Bivalacqua TJ, Partin AW, Lim SJ, Chapman C, Abdallah R, Levy O, Bhowmick NA, Karp JM, De Marzo A, Isaacs JT, Brennen WN, Denmeade SR.

Stem Cells Transl Med. 2019 May;8(5):441-449. doi: 10.1002/sctm.18-0230. Epub 2019 Feb 8.

38.

Low-intensity extracorporeal shockwave therapy in the treatment of erectile dysfunction following radical prostatectomy: a critical review.

Usta MF, Gabrielson AT, Bivalacqua TJ.

Int J Impot Res. 2019 May;31(3):231-238. doi: 10.1038/s41443-019-0121-3. Epub 2019 Feb 1. Review.

PMID:
30710107
39.

Impact of intravesical therapy for non-muscle invasive bladder cancer on the accuracy of urine cytology.

Gupta M, Milbar N, Tema G, Pederzoli F, Chappidi M, Kates M, VandenBussche CJ, Bivalacqua TJ.

World J Urol. 2019 Oct;37(10):2051-2058. doi: 10.1007/s00345-018-02624-3. Epub 2019 Jan 23.

PMID:
30671639
40.

Evaluating the impact of length of time from diagnosis to surgery in patients with unfavourable intermediate-risk to very-high-risk clinically localised prostate cancer.

Gupta N, Bivalacqua TJ, Han M, Gorin MA, Challacombe BJ, Partin AW, Mamawala MK.

BJU Int. 2019 Aug;124(2):268-274. doi: 10.1111/bju.14659. Epub 2019 Jan 27.

PMID:
30570825
41.

Intratunical Injection of Human Adipose Tissue-Derived Stem Cells Restores Collagen III/I Ratio in a Rat Model of Chronic Peyronie's Disease.

Castiglione F, Hedlund P, Weyne E, Hakim L, Montorsi F, Bivalacqua TJ, De Ridder D, Milenkovic U, Ralph D, Garaffa G, Muneer A, Joniau S, Albersen M; Trauma and Reconstructive Urology Working Party of the European Association of Urology Young Academic Urologists.

Sex Med. 2019 Mar;7(1):94-103. doi: 10.1016/j.esxm.2018.09.003. Epub 2018 Nov 30.

42.

Targeted sequencing of plasmacytoid urothelial carcinoma reveals frequent TERT promoter mutations.

Palsgrove DN, Taheri D, Springer SU, Cowan M, Guner G, Mendoza Rodriguez MA, Rodriguez Pena MDC, Wang Y, Kinde I, Ricardo BFP, Cunha I, Fujita K, Ertoy D, Kinzler KW, Bivalacqua TJ, Papadopoulos N, Vogelstein B, Netto GJ.

Hum Pathol. 2019 Mar;85:1-9. doi: 10.1016/j.humpath.2018.10.033. Epub 2018 Nov 14.

43.

Implications of micropapillary urothelial carcinoma variant on prognosis following radical cystectomy: A multi-institutional investigation.

Mitra AP, Fairey AS, Skinner EC, Boorjian SA, Frank I, Schoenberg MP, Bivalacqua TJ, Hyndman ME, Reese AC, Steinberg GD, Large MC, Hulsbergen-van de Kaa CA, Bruins HM, Daneshmand S.

Urol Oncol. 2019 Jan;37(1):48-56. doi: 10.1016/j.urolonc.2018.10.013. Epub 2018 Nov 13.

PMID:
30446450
44.

Correction: Non-invasive detection of urothelial cancer through the analysis of driver gene mutations and aneuploidy.

Springer SU, Chen CH, Rodriguez Pena MDC, Li L, Douville C, Wang Y, Cohen JD, Taheri D, Silliman N, Schaefer J, Ptak J, Dobbyn L, Papoli M, Kinde I, Afsari B, Tregnago AC, Bezerra SM, VandenBussche C, Fujita K, Ertoy D, Cunha IW, Yu L, Bivalacqua TJ, Grollman AP, Diaz LA, Karchin R, Danilova L, Huang CY, Shun CT, Turesky RJ, Yun BH, Rosenquist TA, Pu YS, Hruban RH, Tomasetti C, Papadopoulos N, Kinzler KW, Vogelstein B, Dickman KG, Netto GJ.

Elife. 2018 Nov 12;7. pii: e43237. doi: 10.7554/eLife.43237.

45.

CD24 regulates cancer stem cell (CSC)-like traits and a panel of CSC-related molecules serves as a non-invasive urinary biomarker for the detection of bladder cancer.

Ooki A, VandenBussche CJ, Kates M, Hahn NM, Matoso A, McConkey DJ, Bivalacqua TJ, Hoque MO.

Br J Cancer. 2018 Oct;119(8):961-970. doi: 10.1038/s41416-018-0291-7. Epub 2018 Oct 17.

46.

Intratunical injection of stromal vascular fraction prevents fibrosis in a rat model of Peyronie's disease.

Castiglione F, Hedlund P, Weyne E, Hakim L, Montorsi F, Salonia A, Bivalacqua TJ, De Ridder D, Milenkovic U, Ralph D, Garaffa G, Muneer A, Joniau S, Albersen M; Trauma and Reconstructive Urology Working Party of the European Association of Urology (EAU) Young Academic Urologists (YAU).

BJU Int. 2019 Aug;124(2):342-348. doi: 10.1111/bju.14570. Epub 2019 Jun 2.

PMID:
30267556
47.

A Role for De Novo Purine Metabolic Enzyme PAICS in Bladder Cancer Progression.

Chakravarthi BVSK, Rodriguez Pena MDC, Agarwal S, Chandrashekar DS, Hodigere Balasubramanya SA, Jabboure FJ, Matoso A, Bivalacqua TJ, Rezaei K, Chaux A, Grizzle WE, Sonpavde G, Gordetsky J, Netto GJ, Varambally S.

Neoplasia. 2018 Sep;20(9):894-904. doi: 10.1016/j.neo.2018.07.006. Epub 2018 Aug 15.

48.

ICUD-SIU International Consultation on Bladder Cancer 2017: management of non-muscle invasive bladder cancer.

Monteiro LL, Witjes JA, Agarwal PK, Anderson CB, Bivalacqua TJ, Bochner BH, Boormans JL, Chang SS, Domínguez-Escrig JL, McKiernan JM, Dinney C, Godoy G, Kulkarni GS, Mariappan P, O'Donnell MA, Rentsch CA, Shah JB, Solsona E, Svatek RS, van der Heijden AG, van Valenberg FJP, Kassouf W.

World J Urol. 2019 Jan;37(1):51-60. doi: 10.1007/s00345-018-2438-9. Epub 2018 Aug 14. Review.

PMID:
30109483
49.

Characterization of voiding function and structural bladder changes in a rat model of neurogenic underactive bladder disease.

Weyne E, Dewulf K, Deruyer Y, Rietjens R, Everaerts W, Bivalacqua TJ, De Ridder D, Van der Aa F, Albersen M.

Neurourol Urodyn. 2018 Jun;37(5):1594-1604. doi: 10.1002/nau.23517. Epub 2018 Feb 7.

PMID:
30105760
50.

Editorial Comment.

Kates M, Bivalacqua TJ.

J Urol. 2018 Nov;200(5):1011-1012. doi: 10.1016/j.juro.2018.05.157. Epub 2018 Jul 29. No abstract available.

PMID:
30063891

Supplemental Content

Loading ...
Support Center